A simultaneous webcast of the conference call will be available on the Investor Relations tab of the Ascendis Pharma website at www.ascendispharma.com. About Ascendis Pharma A/S Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of...
By a News Reporter-Staff News Editor at Biotech Week Blaze Bioscience, the Tumor Paint Company , a biotechnology company focused on guided cancer therapy, announced expansion of its Phase 1 program into multiple additional tumor types. The study is currently active at Overlake Medical Center in Bellevue, WA under the direction of principal inve
Bristol-Myers Squibb Company reported that Daklinza, an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration. According to a release from the company, this approval marks the first time patients with chronic hepatitis C virus genotype 3 have a 12- week, once-daily, all-oral treatment option. "The U.S. appr
C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer, today announced US Food and Drug Administration 510 clearance for the Coldplay Cryoballoon? Full Ablation System and the Coldplay Cryoballoon? Swipe Ablation System. The clearance of Coldplay Cryoballoon Full and Swipe Systems is an imp
The Consortium will connect academic and clinical researchers at the University of Cambridge, the Babraham Institute and the Wellcome Trust Sanger Institute with pharmaceutical companies Astex Pharmaceuticals, AstraZeneca and GlaxoSmithKline. Professor Tony Kouzarides from the University of Cambridge, who will head the Therapeutics Consortium and..
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today the formation of a clinical advisory board. Abou-Alfa is an associate professor of
Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended June 30, 2015 and provided an update on recent corporate developments. Two additional studies were presented on Cempra's ot
-Ciclofilin Pharmaceuticals Inc., a hepatitis B virus drug developer, announced today its lead antiviral drug candidate demonstrated significantly reduced liver HBV DNA in a transgenic mouse model. The study was conducted by the National Institute of Allergy and Infectious Diseases, one of the centers within the National Institutes of Health.
Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the second quarter ended June 30, 2015, after the market close on Wednesday, August 5, 2015. Conatus will host a conference call and audio webca
-Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced positive topline interim results from its Phase 2 a study designed to determine the pharmacokinetics, pharmacodynamics and safety and tolerability of its...
CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus infection, today announced that the Company's QA/QC expert, Dr. Robert Schiff, has approved for release inventory suitable to satisfy CytoDyn's current Phase 3 trial. Nader Pourhassan, President and CEO, commented: "We are
PARSIPPANY, N.J. and BERKELEY, Calif., July 29, 2015/ PRNewswire/ Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, announced today that The New England Journal of Medicine published clinical trial results demonstrating that the investigational drug, PLX3397, an oral targeted CSF-1R inhibitor, induced prolonged tumor
Generic drugs maker Hikma Pharmaceuticals jumped 241 p to 2321 p as analysts applauded its pounds sterling 1.7 bn acquisition of Roxane Laboratories, the US generic drugs arm of Germany's Boehringer Ingelheim, making it the sixth largest company by revenue in the US generics market. It follows Teva's pounds sterling 26 bn purchase of Allergan's gen
Easton Pharmaceuticals Inc. announces the appointment of Evan Karras as CEO& Director and announces Mr. Easton Pharmaceuticals is pleased to announce the appointment of highly successful businessman, Evan Karras as CEO& Director, replacing Carla Pepe, who will assume the role of Secretary and Director. Mr. Karras stated, "Timing is everything, and
Release date- 28072015- The U.S. Food and Drug Administration today approved a new balloon device to treat obesity without the need for invasive surgery. The ReShape Integrated Dual Balloon System is intended to facilitate weight loss in obese adult patients. 'For those with obesity, significant weight loss and maintenance of that weight loss often
By a News Reporter-Staff News Editor at Biotech Week Ferring Pharmaceuticals announced that it will collaborate with Baltimore- based Intralytix, Inc. in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease. To explore the possibility that bacteriophages could be used to combat
By a News Reporter-Staff News Editor at Biotech Week SingaporeA made-in- Singapore cancer drug has advanced into clinical trials, charting a milestone in Singapore's biomedical sciences initiative that will go towards improving the lives of cancer patients in Singapore, and worldwide. This is the first publicly-funded drug candidate discovered
Flexion Therapeutics, Inc. today announced that it has completed enrollment of 486 patients in the Phase 3 clinical trial of its lead compound FX006 approximately three months earlier than anticipated, and the company now plans on reporting topline data from this trial in the first quarter of 2016. This study will complete the requisite clinical
Foundation Medicine, Inc. today reported financial and operating results for its second quarter ended June 30, 2015. Foundation Medicine reported total revenue of $22.5 million in the second quarter of 2015, compared to $14.5 million in the second quarter of 2014 and $19.3 million in the first quarter of 2015. Revenue from clinical testing in the s
Galapagos NV announced today that at week 24, patients treated with the selective JAK1 inhibitor filgotinib showed further improvement in signs and symptoms of rheumatoid arthritis activity, as demonstrated by improved ACR responses, DAS28, and other scores, compared to week 12 in the DARWIN 1 Phase 2 B methotrexate add-on study. In this study, f
Naloxone nasal spray is expected to be the first FDA- approved intranasal naloxone product indicated to treat opioid overdose in the United States. "As the rate of opioid overdoses and their profound impact on communities nationwide continues to rise, naloxone nasal spray may help make every life-saving second count by potentially allowing anyone-
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, such as primary biliary cirrhosis and nonalcoholic steatohepatitis, today announced that it will report second quarter 2015 financial results after the...
KaloBios Pharmaceuticals, Inc., a monoclonal antibody company focused on developing innovative therapies to benefit patients with diseases of unmet medical need, with a focus on oncology, announced today that the U.S. Food and Drug Administration has cleared the company's investigational new drug application for KB003, an anti-GM-CSF monoclonal a
Lightlake Therapeutics Inc., a specialty pharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited, Lightlake's partner for treating opioid overdose with intranasal naloxone, has submitted a New Drug Application to the U.S. Food and Drug Administration for Narcan
July 29 Marin County officials launched a new front in the war on prescription drug abuse Tuesday, saying pharmaceutical firms should pay for the safe disposal of old pills and medications. A spokeswoman for the California Retailers Association pledged cooperation. The board agreed with Supervisor Katie Rice, who called the measure a model of col